https://www.selleckchem.com/products/dn02.html
Our phase II AKI rate (0.6%) was significantly lower than our preprotocol rate (6.2%, P 0.01) and statistically similar to our phase I rate (1.2%, P = 0.61). Our hypotension rate in phase II (6.8%) was significantly lower than our preprotocol rate (12.7%, P 0.01) but statistically similar to our phase I rate (5.9%, P = 0.4. Furthermore, a significant decrease was observed in hospital length of stay (P 0.01) over time, but no difference was observed in readmission (P = 0.59) and mortality rates (P = 1.0 over time. This pr
Like
Comment
Share
